AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05320913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group(PENG) block combined with periarticular multimodal drug injection (PMDI)
Description: periarticular local anesthetic infiltration with 120 mg of ropivacaine, epinephrine 0.2 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 40 mL. + PENG block with ropivacaine 40 mg and epinephrine 0.1 mg with normal saline to a total volume of 20 mL
Study NCT05320913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isolated periarticular multimodal drug injection (PMDI)
Description: periarticular local anesthetic infiltration with 150 mg of ropivacaine, epinephrine 0.3 mg and 30 mg of ketorolac diluted with normal saline to a total volume of 50 mL
Study NCT05547191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChloraSolv
Description: Debridement with ChloraSolv until the wound is visually assessed as clean.
Study NCT06569147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab administered subcutaneously for 6 cycles of treatment with 28 days in a treatment cycle
Study NCT05051878 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-scan
Description: occlusal analysis T-scan
Study NCT05051878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: articulating paper
Description: articulating paper occlusal analysis
Study NCT04788537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training to Understand and Navigate Emotions and Interactions (TUNE In)
Description: A three-part cognitive behavioral treatment strategy to improve social functioning in adults with autism spectrum disorder. TUNE In includes components to address the many behavioral domains involved in social functioning, including social motivation, social anxiety, social cognition, social skills, and generalization of the skills to community settings.
Study NCT05391659 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep learning
Description: a form of artificial intelligence (AI), has been introduced for automated analysis of images
Study NCT05391659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: remote grading of fundus images
Description: referrable cases identified by DR AI tool will be remotely graded by a human
Study NCT05391659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: gold standard
Description: examination by ophthalmologist
Study NCT06393764 — intervention group
Intervention type: OTHER
Intervention: Collection of biological samples
Description: Collecte of blood and urine samples
Study NCT06080659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: functional MRI
Study NCT06080659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: functional MRI
Study NCT06080659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
Study NCT06080659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CONFMEM
Description: The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).
Study NCT05021536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Comparator
Study NCT05021536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: Proprietary formulation of taurursodiol and sodium phenylbutyrate
Study NCT04692506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The study product is probiotic
Study NCT04692506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: The study product is probiotic
Study NCT05205837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg, hCG
Description: Drug -Treatment Intramuscular injektion - Treatment
Study NCT05954377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quarterly remote motivational interviews
Description: Remote motivational interview will be in the form of quarterly telephone call (at 3, 6 and 9 months after the start of annual follow up; the patient is seen again at 12 months as part of the annual follow-up) and this for 4 years. It will be performed by medical staff trained in motivational interviewing and who have completed at least 40 hours training in therapeutic education
Study NCT05460871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: participants will receive pregabalin orally 75mg twice daily x 7 days prior to surgery, then 150mg twice daily x 7 days after surgery, followed by 75mg twice daily x 7 days, then stop.
Study NCT05205837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug - Placebo Intramuscular injektion - placebo
Study NCT05781308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² every 3 weeks
Study NCT05781308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m² every 3 weeks
Study NCT05781308 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg every 3 weeks
Study NCT05781308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg every 3 weeks
Study NCT05196100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amparo confidence socket
Description: Confidence socket involves thermoplastic material being moulded onto the patient's residual limb and a socket is produced in a single session. The socket can be remoulded to adjust to changes in residual limb volume.
Study NCT05744700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulinase
Description: Participants will consume one capsule containing 1,000 INU inulinase, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
Study NCT05744700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: Participants will consume one capsule containing maltodextrin, twice daily, for 28 days. Participants will be directed to consume the capsules with their two largest meals.
Study NCT05716373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain
Description: reiki
Study NCT05288517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lock to Live
Description: Lock to Live is an anonymous web-based self-administered decision aid for safe firearm and medication storage (Public URL: http://lock2live.com/).
Study NCT05301556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product
Description: * Before the surgery: FSMP provides daily target energy needed by participants~* 1-2 days after surgery: Start FSMP and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase FSMP intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. FSMP provides daily target energy needed by participants
Study NCT05781308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg every 3 weeks
Study NCT04716634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
Study NCT04716634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
Study NCT05130801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pHLIP® ICG NIRF imaging
Description: Pre-operative research MRI will be performed 1-3 weeks prior to the surgery. single pHLIP® ICG injection will be administered i.v. by a radiologist on the protocol one day prior to scheduled surgery on the occasion of presurgical localization (12-36 hours prior to the surgery).~In Phase I, we propose to investigate 4 different doses:~Dose level 1 = 0.04 mg/kg Dose level 2 = 0.075 mg/kg Dose level 3 = 0.15 mg/kg Dose level 4 = 0.30 mg/kg~In Phase IIa, the researchers propose to administer selected in Phase I dose of pHLIP® ICG. In Phase IIa, the researchers propose to administer pHLIP® ICG at DL2, DL3 or DL4 at different time points prior to surgery ranging from 12-110 hours, with targeted enrollment of 12 patients. Next, the selected optimal dose and timing will be used with targeted enrollment of 28 patients. The total number of subjects in Phase IIa study is 40.
Study NCT05301556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product
Description: * Before surgery: TPF-T provides daily target energy needed by participants~* 1-2 days after surgery: Start TPF-T and advance as tolerated to achieve 20% of the daily target energy needed by participants~* 3rd-5th day after surgery: Gradually increase TPF-T intake every day as tolerated to provide 30-80% of the daily target energy needed by participants~* 6th to 11th day after surgery. TPF-T provides daily target energy needed by participants
Study NCT06484530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine
Description: 1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.
Study NCT05192070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussive Massage Group
Description: Quadriceps, hamstring and gastrocnemius muscles of the participants will done massage for 3 minutes with a hypervolt massage device.
Study NCT06523855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation
Description: bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
Study NCT06523855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral alveolar cleft grafting using iliac crest particulate and microplate fixation
Description: bilateral alveolar cleft grafting using particulate iliac crest graft accompanied with fixation of graft and premaxilla using microplate
Study NCT04919382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04919382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT06620614 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% Heavy Bupivacaine
Description: There are two groups.
Study NCT06620614 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5% Heavy Bupivacaine
Description: There are two groups.
Study NCT06629051 — intervention group
Intervention type: DRUG
Intervention: Berberine Hydrochloride
Description: post-intervention of berberine
Study NCT06629051 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Looks the same as berberine
Study NCT05404230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Fish oil containing poly unsaturated fatty acids.
Study NCT05404230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: Corn oil
Study NCT06390592 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PD cycler
Description: Patients are treated continuously during Peritoneal dialysis with the PD cycler sleep•safe harmony with different FlexPoint settings.~According to their randomization the patients are treated with Treatment A, B or C in a different order:~* standard (default) FlexPoint settings (Treatment A)~* minimum value FlexPoint settings (Treatment B)~* maximum value for permitted peritoneal residual volume (50%) of FlexPoint settings (Treatment C)
Study NCT04614584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 30 mg PO daily x 4 days
Study NCT04614584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Description: Methamphetamine 30 mg IV once
Study NCT04614584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: Methamphetamine 30 mg IV once
Study NCT05192070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic stretching group
Description: Dynamic stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
Study NCT05192070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching group
Description: Static stretching will be performed for the quadriceps, hamstring and gastrocnemius muscles of the participants with 10 repetitions.
Study NCT06571864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD38 Monoclonal Antibody
Description: Anti-CD38 Monoclonal Antibody: Daratumumab is intravenously given at the dose of 16 mg/kg weekly for 8 weeks, then every two weeks for 8 more times, and lastly monthly until the 52nd week (8 more administrations)
Study NCT06230913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: To perform taping of the chest, the patient was asked to stand upright with the affected shoulder rotated externally. Five straps of the fan shaped tape were extended to the chest toward the affected axilla with 15% to 20% tension, and the anchor was positioned without tension in the anterior axilla on the sound side.
Study NCT04890964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Study NCT04890964 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Study NCT04890964 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: A stimulation device, that releases 2.0mA current by a 35 cm2 electrode direct located on a specific location on the scalp for 20 minutes
Study NCT06466005 — intervention group
Intervention type: OTHER
Intervention: UnityPhilly app
Description: UnityPhilly automatically connects bystanders and victims of opioid overdose with nearby community members who can respond immediately with naloxone.
Study NCT06230913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure garment
Description: The skin was washed and dried before applying the PG. The Premium Lymphedema Gradient Garment (Jobskin, Long Eaton, England) was used to apply PGs. This garment has a pressure gradient built into it, applying between 20 and 60 mm Hg for at least 15 to 18 hours each day for three weeks. The gradient counter pressure is applied using a gram tension.
Study NCT05704088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: randomized control trial, study group will receive dapagliflozin tablets
Study NCT05704088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: randomized control trial, control group will receive placebo tablets
Study NCT04714177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol
Description: Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
Study NCT04714177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage
Study NCT06165731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercises
Description: Mindful deep breathing cycle comprised of a 3-second inhale causing abdominal wall movement followed by a 5-second exhale, which will be completed for a total of 10 minutes of daily exercise
Study NCT06165731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Hygiene Education
Description: Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
Study NCT06165731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Hygiene Education
Description: Educational handout on bladder health and hygiene with recommendations endorsed by the International Urogynecologic Association
Study NCT05283460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mandala
Description: The Life Satisfaction Scale was administered to patients in the control group at the first encounter (pre-test) and three weeks after the first encounter (post-test). Although the pre- and post-test treatment protocols were the same for both intervention and control groups, the only difference between their treament was the mandala activity, which was not applied to those in the control group. Patients in the control group continued their routine lives at home for three weeks. After the application, the mandala activity was applied to all patients who wanted it.
Study NCT06353958 — intervention group
Intervention type: DRUG
Intervention: MiSaver
Description: MiSaver vials was thawed using a thermostat-controlled mini bath, drawn into a 20ml syringe, and diluted with normal saline and intravenous infused following standard operating procedures, consecutively, until reasching the dosage.~Patients were premedicated with intravenous antihistamines (such as diphenhydramine) and corticosteroids (such as hydrocortisone) 30-60 minutes before the stem cell infusion. Any unused solution was discarded, and the total volume of injected solution was adjusted to accommodate the total daily fluid volume administered.
Study NCT05202028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
Study NCT05202028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage
Description: After the physical therapy applied to the patient by the physiotherapist in the special education center, 3 days a week for 8 weeks, once a day for approximately 15-20 minutes. Connective tissue massage will be applied. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
Study NCT05202028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic abdominal massage
Description: After the physical therapy applied to the patient by the physiotherapist in the special education center for 8 weeks, 3 days a week for about 15-20 minutes. reflexology will be practiced. To families; Training will be given on sleep hygiene, nutritional recommendations and lifestyle changes.
Study NCT06536504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steinway Spirio M recording/player piano
Description: Patients will be equally randomized into one of the three arms (simulated live music, recorded music, or no music) applying the random permutated block. Randomization will be conducted via an approved institutional database with the randomization list generated by the study statistician.
Study NCT04836793 — intervention group
Intervention type: OTHER
Intervention: Additional biological samples
Description: Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected
Study NCT06693492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention
Description: Both chronic and post-acute patients are evaluated through the ultrasound technique to further characterize the mechanisms underlying DOC following acquired brain injuries (e.g., stroke, traumatic brain injury, anoxic events). Furthermore, the predictive value of structural and functional markers for DOC chronicization is explored by following up post-acute DOC patients 1 year after the acute event. Finally, to innovate the therapeutic approach to DOC patients, we adopt the low-intensity focused ultrasound (FUS) on a group of selected 10 patients out of the 100 DOC patients enrolled in the study to modulate brain networks' functioning targeting key brain structures for the recovery of consciousness.
Study NCT04588285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Oral ambroxol medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
Study NCT04588285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo medication (60 mg) from day 1 to study end (at 60 mg TID (day 1-7), 120 mg TID (day 8- 14), 315 mg BID (day 15-21), 315 mg TID (day 22-28) and 420 mg TID (day 29-550)
Study NCT06327425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetocardiography
Description: Magnetocardiography